Continuous showed no clear difference in all‐cause mortality compared with intermittent Antibiotic Infusions (moderate certainty).
Continuous showed no clear difference in infection recurrence compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in clinical cure compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in super‐infection compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in serious adverse events compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in withdrawal due to adverse events compared with intermittent Antibiotic Infusions (low certainty).
It is very uncertain whether continuous changes adverse events compared with intermittent Antibiotic Infusions (very low certainty).
It is very uncertain whether the intervention changes re‐infection (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent bacteriuria compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent symptoms compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes persistent bacteriuria compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes recurrence compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes persistent bacteriuria and symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether single‐dose changes recurrence compared with conventional 10‐day antibiotic treatment (very low certainty).
It is very uncertain whether the intervention changes persistent bacteriuria (very low certainty).